What You Should Know:
- New company Velsera was announced at the J.P. Morgan Healthcare Conference supported by thematic-focused impact fund Summa Equity (“Summa”).
- Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world. Velsera creates a software platform out of science, technology, and informatics, making data actionable, accelerating the pace and potential of multi-omics.
- Velsera, headquartered in
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
AWS Launches Amazon Omics for Precision Medicine
What You Should Know:
- AWS announced the launch of a new service, Amazon Omics, to help bioinformaticians, researchers, and scientists store, query, and analyze genomic, transcriptomic, and other omics data and generate insights to improve health and advance scientific discoveries.
- The explosion of “omics” data, such as genomic, transcriptomic, and proteomic data, is driving a new understanding of biology at the molecular level. This, in combination with
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know:
- Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records.
- Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Assisted Polyp Detection Device Receives FDA Clearance
What You Should Know:
- Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced recently that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance.
- The device was evaluated in the largest U.S.-based multicenter clinical study for a
Read More
Children’s Oncology Group Taps Tempus to Provide Genomic Sequencing for Pediatric Cancer Patients
What You Should Know:
-Tempus, an $8B precision medicine company, is providing genomic sequencing for 300 eligible pediatric cancer patients annually through their new collaboration with the Children’s Oncology Group (COG). Tempus’ support for COG – a leader in pediatric oncology research – will assist with matching patients to clinical trials like the Pediatric MATCH Screening Trial APEC1621SC (NCT03155620), which is studying the effectiveness of genetic testing-directed treatment in
Read More
Techstars Relaunches Healthcare Accelerator in Los Angeles
What You Should Know:
- Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs announces today the relaunch of Techstars Healthcare sponsored by Cedars-Sinai, Point32Health, UCI Health, and UnitedHealthcare.
- The consortium-led accelerator program will be based in Los Angeles and select 12 high-growth startups to participate in its intensive 13-week program. Startups will receive capital,
Read More
What is the Potential for Digital Twins in Healthcare?
Digital twins are virtual representations of an object or system that spans its lifecycle, is updated from real-time data, and use simulation, machine learning and reasoning to help decision-making (IBM). In most cases, this helps data scientists understand how products are operating in production environments and anticipate how they may behave overtime. But what happens when a digital twin is that of a human being?
By using digital twins to model a person, you can use technologies like
Read More
How Medical Researchers Can Leverage Tech to Help Streamline Biospecimen Matchmaking and Procurement
Many medical advancements – from life-saving vaccines and treatments to new diagnostic tests like liquid biopsies – are built on research that involves human biospecimens. Biofluids, tissue and cells are indispensable resources for the medical researcher, yet the process of sourcing these biospecimens can be woefully frustrating and inefficient. These challenges can have a direct, negative impact on the pace of discovery, creating urgency for improved access to the biospecimens researchers need
Read More
Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures
What You Should Know:
Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures.
Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Syapse Raises $35M to Expand Learning Health Network
What You Should Know:
- Syapse raises $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus)to tackle the challenge of understanding, preventing, and treating complex cancers.
- The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the
Read More
